Cargando…
Design, Synthesis, In Silico Studies and Inhibitory Activity towards Bcr-Abl, BTK and FLT3-ITD of New 2,6,9-Trisubstituted Purine Derivatives as Potential Agents for the Treatment of Leukaemia
We report 31 new compounds designed, synthesized and evaluated on Bcr-Abl, BTK and FLT3-ITD as part of our program to develop 2,6,9-trisubstituted purine derivatives as inhibitors of oncogenic kinases. The design was inspired by the chemical structures of well-known kinase inhibitors and our previou...
Autores principales: | Bertrand, Jeanluc, Dostálová, Hana, Kryštof, Vladimír, Jorda, Radek, Delgado, Thalía, Castro-Alvarez, Alejandro, Mella, Jaime, Cabezas, David, Faúndez, Mario, Espinosa-Bustos, Christian, Salas, Cristian O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228270/ https://www.ncbi.nlm.nih.gov/pubmed/35745866 http://dx.doi.org/10.3390/pharmaceutics14061294 |
Ejemplares similares
-
Promising 2,6,9-Trisubstituted Purine Derivatives for Anticancer Compounds: Synthesis, 3D-QSAR, and Preliminary Biological Assays
por: O. Salas, Cristian, et al.
Publicado: (2019) -
Synthesis and Structural Optimization of 2,7,9-Trisubstituted purin-8-ones as FLT3-ITD Inhibitors
por: Tomanová, Monika, et al.
Publicado: (2022) -
Synthesis and Pharmacophore Modelling of 2,6,9-Trisubstituted Purine Derivatives and Their Potential Role as Apoptosis-Inducing Agents in Cancer Cell Lines
por: Calderón-Arancibia, Jeannette, et al.
Publicado: (2015) -
Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia
por: Pillinger, Genevra, et al.
Publicado: (2015) -
Novel 2,6,9-Trisubstituted Purines as Potent CDK Inhibitors Alleviating Trastuzumab-Resistance of HER2-Positive Breast Cancers
por: Kuchukulla, Ratnakar Reddy, et al.
Publicado: (2022)